质谱法与免疫固定电泳在多发性骨髓瘤治疗监测中的比较
在新诊断多发性骨髓瘤患者中,于基线、诱导后、自体干细胞移植后和巩固后采集血清,比较免疫固定电泳(IFE)与质谱法(EXENT&FLC-MS)检测M蛋白的一致性及对无进展生存(PFS)的预测能力。质谱法更敏感,且在巩固后能区分IFE无法区分的不同PFS队列。
要点
- 基线时两种方法同种型完全匹配的样本占82.1%。
- 巩固后IFE无法区分不同中位PFS的2个队列,而质谱法可以区分。
- 在IFE阴性患者中,质谱法识别出2组中位PFS显著不同(P = .0008)。
核心结论
- 与IFE相比,EXENT&FLC-MS在基线和治疗期间检测多发性骨髓瘤患者M蛋白均更敏感,并能更准确预测患者结局。
研究设计与样本
- 研究纳入PETHEMA/GEM2012MENOS65试验中新诊断的多发性骨髓瘤患者,采集基线(n = 223)、诱导后(n = 183)、自体干细胞移植后(n = 173)和巩固后(n = 173)的血清样本。
- 对上述血清样本同时应用免疫固定电泳(IFE)和质谱法(EXENT&FLC-MS)进行检测。
主要发现
- 基线时两种方法识别的同种型在82.1%的样本中完全匹配;其余样本中除2例外,EXENT&FLC-MS均提供了IFE之外的额外M蛋白信息。
- 总体上EXENT&FLC-MS与IFE的结果在超过80%的病例中一致,大多数不一致为EXENT&FLC-MS阳性而IFE阴性。
- 巩固后IFE无法区分2个中位无进展生存期(PFS)不同的队列,而EXENT&FLC-MS可以区分。
- 在IFE阴性患者中,EXENT&FLC-MS识别出2组中位PFS显著不同(P = .0008)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE- cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE- patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.
引用
- Puig N, Contreras MT, Agulló C, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022. PMID: 35157768. doi:10.1182/bloodadvances.2021006762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。